Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
Fuchs endothelial corneal dystrophy Indication Strategy Report 2026: TCF4, Trials and Deals
23 July 2026
2026 Fuchs endothelial corneal dystrophy strategy: epidemiology, TCF4 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Best disease Indication Strategy Report 2026: BEST1, Trials and Deals
23 July 2026
2026 Best disease strategy: epidemiology, BEST1 biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized with…
Latest Hotspot
8 min read
Cone-rod dystrophy Indication Strategy Report 2026: ABCA4, Trials and Deals
23 July 2026
2026 Cone-rod dystrophy strategy: epidemiology, ABCA4 biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized…
Latest Hotspot
8 min read
Leber congenital amaurosis Indication Strategy Report 2026: RPE65, Trials and Deals
23 July 2026
2026 Leber congenital amaurosis strategy: epidemiology, RPE65 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
X-linked retinitis pigmentosa Indication Strategy Report 2026: RPGR, Trials and Deals
23 July 2026
2026 X-linked retinitis pigmentosa strategy: epidemiology, RPGR biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Usher syndrome type 1B Indication Strategy Report 2026: MYO7A, Trials and Deals
23 July 2026
2026 Usher syndrome type 1B strategy: epidemiology, MYO7A biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Blue cone monochromacy Indication Strategy Report 2026: OPN1LW, Trials and Deals
23 July 2026
2026 Blue cone monochromacy strategy: epidemiology, OPN1LW biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Achromatopsia Indication Strategy Report 2026: CNGA3, Trials and Deals
23 July 2026
2026 Achromatopsia strategy: epidemiology, CNGA3 biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized with…
Latest Hotspot
8 min read
Choroideremia Indication Strategy Report 2026: CHM, Trials and Deals
23 July 2026
2026 Choroideremia strategy: epidemiology, CHM biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized with…
Latest Hotspot
8 min read
Inherited retinal dystrophy Indication Strategy Report 2026: RPE65, Trials and Deals
23 July 2026
2026 Inherited retinal dystrophy strategy: epidemiology, RPE65 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Central serous chorioretinopathy Indication Strategy Report 2026: Mineralocorticoid receptor, Trials and Deals
23 July 2026
2026 Central serous chorioretinopathy strategy: epidemiology, Mineralocorticoid receptor biology, clinical competition, recent deals, unmet need and market…
Latest Hotspot
8 min read
Shigellosis Indication Strategy Report 2026: Shigella LPS, Trials and Deals
23 July 2026
2026 Shigellosis strategy: epidemiology, Shigella LPS biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized…